- The New Normal Amid the SARS-CoV-2 Pandemic: Contributions From a High-Complexity Diagnostic Laboratory
The New Normal Amid the SARS-CoV-2 Pandemic: Contributions From a High-Complexity Diagnostic Laboratory
As the COVID-19 outbreak began to greatly impact our global society, medical companies were forced to rapidly respond – keeping patients at the core of their actions, while being called to develop medical solutions amid a pandemic. We have gained critical takeaways from this topic over the past months, and we would love to share them with you – allowing us to collaboratively fight this global crisis together.
Watch our recent webinar, ‘The New Normal Amid the SARS-CoV-2 Pandemic: Contributions From a High-Complexity Diagnostic Laboratory,’ to learn how CENTOGENE successfully set up a SARS-CoV-2 detection laboratory and overcame the logistics and obstacles of developing a high-throughput, high-quality diagnostic test. Moreover, you will also find out about how multiomic research may be able to unlock the mysteries surrounding COVID-19.
- Lessons from successfully setting up a SARS-CoV-2 laboratory
- Global expansion of SARS-CoV-2 detection testing
- Spearheading multiomic research to unlock the mysteries surrounding COVID-19
Dr. Peter Bauer, Chief Genomic Officer
Prof. Peter Bauer, MD, serves as CENTOGENE’s Chief Genomic Officer, where he combines clinical and medical understanding in genetic testing with an excellent knowledge of the latest scientific development, based on his extraordinary experience, especially in high-throughput genetic testing using next-generation sequencing.
Prof. Bauer received his board certification in Human Genetics in 2006 and headed the molecular diagnostic laboratory at the Institute of Medical Genetics and Applied Genomics at the University Hospital Tübingen. Additionally, he is Vice President of the German Society of Neurogenetics (DGNG). Peter has authored more than 140 publications in neurogenetics, oncogenetics, cardiogenetics, and sequencing technology.